generation run 2026-05-11
61 min completedmodel pipeline-v5plan not recordedrun/409d3f84…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- structural_inference
Reproduce
- inputs
- 28 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
17 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | synthetic cathinone monoamine transporter structure-activity DAT NET SERT | 2 | 2 | Key pharmacology references for cathinone class mechanism |
| 2 | PubMed · absence | ethcathinone ETH-CAT cathinone pharmacology | 0 | — | No specific pharmacology papers found under this query |
| 3 | ClinicalTrials.gov · absence | ethcathinone cathinone stimulant | 0 | — | No clinical trials registered |
| 4 | OpenAlex | ethcathinone stimulant cathinone | 109 | 4 | High-citation review articles providing context on synthetic cathinone pharmacology |
| 5 | PubMed | ethcathinone 2-ethylamino-1-phenylpropan-1-one | 15 | 9 | Selected papers with direct mention of ethcathinone for forensic, detection, and pharmacology relevance |
| 6 | PubChem | ethcathinone | 1 | 1 | Primary chemical identity data |
| 7 | WebSearch | ethcathinone Australia Canada legal status controlled substance | 10 | 2 | Legal status verification |
| 8 | HandWiki | ethcathinone | 1 | 3 | Rich chemical and legal data not fully available via API tools |
| 9 | WebSearch | ethcathinone party pills sold ecstasy Cairns Australia mephedrone | 10 | 1 | Historical market appearance and use context |
| 10 | PubMed | new psychoactive substances NPS serotonin syndrome systematic review | 2 | 2 | Relevant to safety, toxicology, and drug interaction sections |
| 11 | PubMed | diethylpropion amfepramone metabolism pharmacokinetics human | 8 | 3 | Pharmacokinetic data showing ethcathinone as active metabolite of licensed drug diethylpropion |
| 12 | PubMed | diethylpropion amfepramone metabolism pharmacokinetics human | 8 | 3 | Pharmacokinetic pathway for ethcathinone from licensed drug |
| 13 | WebSearch | ethcathinone pharmacology NET DAT EC50 Ki binding affinity | 10 | 2 | Primary pharmacological mechanism data |
| 14 | WebFetch | — | 1 | 2 | Government harm assessment provides detection epidemiology and legal status confirmation |
| 15 | PubMed | ethcathinone party pills capsule identification forensic | 1 | 1 | Historical market appearance documentation for ethcathinone |
| 16 | PubMed | synthetic cathinone NPS serotonin syndrome systematic review; cathinone neurotoxicity | 2 | 2 | Safety, toxicology and drug interaction context |
| 17 | WebSearch | ethcathinone hyponatremia seizures clinical case report | 10 | 1 | CRITICAL: first and primary clinical toxicology case report involving ethcathinone |
71 claims by section — every cited sentence, checked against its source
safety26 · 19 ok
Wastewater screening in Slovenian educational institutions confirmed ongoing use in 2023supported
Ethcathinone unequivocally identified by LC-IMS-HRMS in wastewater from educational institutions in Slovenia. j.envres.2023.117061
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
The sole published clinical case report of ethcathinone-associated toxicity involved a 22-year-old woman who ingested a product containing both ethcathinone and methylone alongside three alcoholic beveragessupported
First reported case of ethcathinone and methylone poisoning in medical toxicology literature. 22-year-old woman, recurrent tonic-clonic seizures, severe hyponatremia (120 mmol/L), rhabdomyolysis (CK 34,537 U/L). s13181-011-0159-1
Claim in safety — inconclusiveinconclusiveworking →
The rhabdomyolysis documented in the Boulanger-Gobeil case (CK = 34,537 U/L) aligns with this class pattern.supported
rhabdomyolysis (CK 34,537 U/L) s13181-011-0159-1
Polish forensic data (2012–2014) identified it in 5 of 112 NPS-positive cases, typically alongside other substancessupported
Ethcathinone found in 5 of 112 NPS cases in Poland 2012-2014. dta.1924
Acute psychiatric effects: Agitation, confusion, psychosis, paranoid ideation, hallucinations, and delirium.partially supported
Chronic use induces acute psychosis, hypomania, paranoid ideation, delusions. fpsyt.2017.00156
Neurological emergencies: A systematic review of synthetic cathinone neurotoxicity documents encephalopathy, coma, convulsions, excited delirium syndrome, and serotonin syndrome.supported
Adverse effects include encephalopathy, coma, convulsions, sympathomimetic toxidrome, excited delirium syndrome, serotonin syndrome. ijms24076230
Chronic use effects: Weinstein et al. report that chronic synthetic cathinone use "can have major effects on the central nervous system and can induce acute psychosis, hypomania, paranoid ideation, and delusions".supported
Chronic use induces acute psychosis, hypomania, paranoid ideation, delusions. fpsyt.2017.00156
The seizure observed in the clinical case report was attributed to acute hyponatremia rather than direct ethcathinone neurotoxicity, but the possibility of direct seizure threshold reduction at high doses — a class-level cathinone risk — cannot be excluded.supported
22-year-old woman, recurrent tonic-clonic seizures, severe hyponatremia (120 mmol/L). s13181-011-0159-1
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
ICSS threshold studies with the close analog 4-methylethcathinone (4-MEC) show brain reward circuit activation in rats at lower potency than methamphetamine or α-PVP, consistent with a moderate rather than high reinforcement signal.supported
4-MEC (4-methylethcathinone, closely related to ethcathinone) reduces ICSS thresholds in rats. Potency: methamphetamine ≈ alpha-PVP > 4-MEC. pyu014
Ethcathinone's NET-preferential profile with weak DAT activity predicts lower abuse liability than DAT-preferential cathinones, as reinforcing properties of stimulants correlate primarily with dopamine efflux magnitudesupported
Three pharmacological groups identified based on DAT/SERT selectivity. j.1476-5381.2012.02145.x
Ripple et al. documented the first tramadol-related death via serotonin-mediated seizures in combination with other serotonergic drugssupported
First reported tramadol-related death via serotonin-mediated seizures. Tramadol combined with venlafaxine, trazodone, quetiapine led to fatal outcome. pmid:11111800
Both compounds release serotonin, creating additive risk for serotonin syndrome, hyperthermia, hyponatremia (particularly if excessive fluid intake occurs, as documented in the clinical case report), and cardiovascular overloadsupported
Systematic review: NPS including synthetic cathinones linked to serotonin syndrome. Classic triad: altered mental status, neuromuscular effects, autonomic hyperactivity. j.expneurol.2021.113638
Both compounds release serotonin, creating additive risk for serotonin syndrome, hyperthermia, hyponatremia (particularly if excessive fluid intake occurs, as documented in the clinical case report), and cardiovascular overloadsupported
severe hyponatremia (120 mmol/L), rhabdomyolysis (CK 34,537 U/L) s13181-011-0159-1
Claim in safety — inconclusiveinconclusiveworking →
This is a class-level contraindication for all monoamine-releasing stimulantssupported
Intoxication reports note concurrent use risk. s00204-020-02693-7
Co-ingestion of multiple novel psychoactive substances — the most common real-world pattern among synthetic cathinone users — represents the highest-risk interaction scenariosupported
Reviews designer drugs including synthetic cathinones. Intoxication reports note concurrent use risk. s00204-020-02693-7
Forensic casework consistently identifies ethcathinone alongside other cathinones and conventional drugs of abuse.supported
Ethcathinone found in 5 of 112 NPS cases in Poland 2012-2014. NPS prevalence ~15-17%, cathinones 88% of NPS cases. dta.1924
Claim in safety — inconclusiveinconclusiveworking →
Seizure disorder (absolute): The clinical case report documents seizures in the context of ethcathinone ingestion. While attributed to hyponatremia, direct seizure threshold reduction is a class-level cathinone risk and cannot be excluded.supported
22-year-old woman, recurrent tonic-clonic seizures, severe hyponatremia (120 mmol/L). s13181-011-0159-1
Hepatic impairment (relative): CYP3A4 involvement in ethcathinone metabolism implies impaired clearance in patients with hepatic dysfunction, potentially prolonging and intensifying effects.supported
CYP3A4 and ABCB1 polymorphisms affect AFP metabolism. Four metabolizer phenotypes identified. s41598-019-54436-z
Psychiatric history — psychosis, mania, severe anxiety (relative): Chronic cathinone use induces psychosis, hypomania, paranoid ideation, and delusions. Pre-existing psychiatric vulnerability increases risk.supported
Chronic use induces acute psychosis, hypomania, paranoid ideation, delusions. fpsyt.2017.00156
history8 · 6 ok
Ethcathinone's presence in khat was confirmed by Shi et al. using HPLC-Q-TOF-MS, identifying it alongside cathinone, methcathinone, norpseudoephedrine, and norephedrine as a psychoactive constituent of dried khat materialsupported
Methcathinone and ethcathinone identified as psychoactive components in khat (Catha edulis), alongside cathinone, norpseudoephedrine, norephedrine. sp.j.1123.2023.03009
Dangor et al. developed a gas-liquid chromatographic method in 1986 specifically to quantify "ethylaminopropiophenone" (ethcathinone) alongside unchanged diethylpropion in human plasma, saliva, and urine, establishing it as a major circulating metabolitesupported
Identifies ethylaminopropiophenone (ethcathinone) as major metabolite of amfepramone in human plasma, saliva and urine. GLC method for simultaneous determination. pmid:3790180
The following year, Beckett and Stanojčić published a quantitative re-evaluation of diethylpropion metabolism demonstrating that mono-N-de-ethylation — the pathway producing ethcathinone — accounts for approximately 35% of the administered dose, with only 3–4% of diethylpropion remaining unchanged after oral administrationsupported
mono-N-de-ethylation is main pathway (~35% of dose) producing ethcathinone. Only 3-4% unchanged drug excreted. pmid:2886596
Chemical analysis by Camilleri et al. confirmed the presence of N-ethylcathinone alongside 4-methylmethcathinone (mephedrone), representing one of the earliest published identifications of either compound in quasi-legal consumer products.supported
Components included mephedrone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone, and N-ethylcathinone (ethcathinone). All unlisted in South Australian controlled substance regulations at time. j.forsciint.2009.12.048
Polish forensic data from 2012–2014 identified ethcathinone in 5 of 112 new psychoactive substance (NPS) cases (4.5%)supported
Ethcathinone found in 5 of 112 NPS cases in Poland 2012-2014. dta.1924
Claim in history — inconclusiveinconclusiveworking →
In 2023, ethcathinone was unequivocally identified in wastewater from educational institutions in Slovenia, confirming ongoing use in younger populationssupported
Ethcathinone unequivocally identified by LC-IMS-HRMS in wastewater from educational institutions in Slovenia. j.envres.2023.117061
Claim in history — inconclusiveinconclusiveworking →
pharmacology8 · 6 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Rat synaptosome release assays further demonstrate that ethcathinone releases norepinephrine and serotonin but does not release dopamine — it blocks DAT uptake without triggering vesicular dopamine effluxsupported
Ethcathinone (NEC) characterized as hybrid DAT blocker and 5-HT releaser. acsptsci.4c00299
Synthetic cathinones are broadly divided into three groups based on DAT/SERT selectivity: (1) DAT-preferential releasers such as cathinone and methcathinone (amphetamine-like), (2) non-selective uptake inhibitors such as mephedrone and methylone (MDMA-like), and (3) highly selective DAT/NET blockers such as MDPV and pyrovaleronesupported
Cathinone, methcathinone, and flephedrone act as preferential DA and NA uptake inhibitors and induce DA release. Three pharmacological groups identified based on DAT/SERT selectivity. j.1476-5381.2012.02145.x
Claim in pharmacology — inconclusiveinconclusiveworking →
Only 3–4% of diethylpropion remains unchanged after oral administrationsupported
Only 3-4% unchanged drug excreted. pmid:2886596
Dangor et al. developed a specific GLC method to quantify ethcathinone ("ethylaminopropiophenone") in human plasma, saliva, and urine alongside unchanged diethylpropionsupported
Identifies ethylaminopropiophenone (ethcathinone) as major metabolite of amfepramone in human plasma, saliva and urine. GLC method for simultaneous determination. pmid:3790180
Sustained-release formulations of diethylpropion produce plateau plasma levels of the active metabolite over 6–8 hours.supported
Sustained release provides plateau levels 6-8h post-dose. pmid:3663274
A pharmacogenetic study in 36 healthy Mexican volunteers demonstrated that CYP3A4 (polymorphism rs2242480) and ABCB1 (polymorphism rs1045642) significantly affect amfepramone pharmacokinetics (p < 0.05), with four distinct metabolizer phenotypes identified (slow, normal, intermediate, fast)supported
Amfepramone pharmacokinetics in 36 healthy Mexicans. CYP3A4 and ABCB1 polymorphisms affect AFP metabolism. Four metabolizer phenotypes identified. s41598-019-54436-z
neuroscience6 · 4 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
The DAT/NET selectivity ratio suggests that ethcathinone produces less mesolimbic reward activation than methcathinone, mephedrone, or MDPV — compounds with stronger DAT releasing or blocking activitysupported
Three pharmacological groups identified based on DAT/SERT selectivity. j.1476-5381.2012.02145.x
However, ICSS threshold data from the close analog 4-MEC demonstrates measurable reward circuit activation in rats, indicating that ethcathinone's reward potential, while lower than that of more dopaminergic cathinones, is not negligible.supported
4-MEC (4-methylethcathinone, closely related to ethcathinone) reduces ICSS thresholds in rats. Potency: methamphetamine ≈ alpha-PVP > 4-MEC. pyu014
Ethcathinone releases serotonin from synaptosomes, suggesting activation of central serotonergic projections from the dorsal raphe nucleussupported
Ethcathinone (NEC) characterized as hybrid DAT blocker and 5-HT releaser. acsptsci.4c00299
If significant, serotonergic activation could contribute to mood elevation, mild entactogenic quality, and the hyponatremia risk documented in the clinical case report (via serotonin-mediated SIADH).supported
severe hyponatremia (120 mmol/L) s13181-011-0159-1
Claim in neuroscience — inconclusiveinconclusiveworking →
summary6 · 4 ok
Claim in summary — inconclusiveinconclusiveworking →
Ethcathinone occupies a singular pharmacological position: it is the primary active metabolite of diethylpropion (amfepramone), a licensed appetite suppressant marketed since the 1950ssupported
Diethylpropion is rapidly and extensively metabolized in humans; mono-N-de-ethylation is main pathway (~35% of dose) producing ethcathinone. pmid:2886596
Ethcathinone also occurs naturally in Catha edulis (khat)supported
Methcathinone and ethcathinone identified as psychoactive components in khat (Catha edulis), alongside cathinone, norpseudoephedrine, norephedrine. sp.j.1123.2023.03009
It first appeared on recreational markets in 2007 in party pill capsules identified in Australiasupported
Four capsules from Neorganics (Israel), delivered anonymously to Royal Adelaide Hospital in August 2007. Components included...N-ethylcathinone (ethcathinone). All unlisted in South Australian controlled substance regulations at time. j.forsciint.2009.12.048
Claim in summary — inconclusiveinconclusiveworking →
The sole published clinical case report involved co-ingestion of ethcathinone with methylone and alcohol, producing seizures, severe hyponatremia (Na⁺ = 120 mmol/L), and rhabdomyolysis (CK = 34,537 U/L) — causal attribution to ethcathinone alone is not possiblesupported
22-year-old woman, recurrent tonic-clonic seizures, severe hyponatremia (120 mmol/L), rhabdomyolysis (CK 34,537 U/L), required intubation. s13181-011-0159-1
chemistry5 · 4 ok
Claim in chemistry — inconclusiveinconclusiveworking →
Hepatic mono-N-de-ethylation converts diethylpropion to ethcathinone.supported
mono-N-de-ethylation is main pathway (~35% of dose) producing ethcathinone. pmid:2886596
X-ray crystallographic analysis of the hydrochloride salt confirmed the racemic nature of commercially encountered ethcathinonesupported
X-ray confirmed both compounds as racemic mixtures. s11419-016-0345-6
Published spectroscopic characterization includes NMR, infrared, and mass spectrometric fingerprint datasupported
Comprehensive chemical characterization for ethcathinone HCl and 4-CEC HCl using NMR, IR, GC-MS, LC-MS, and X-ray crystallography. s11419-016-0345-6
Thermal degradation during gas chromatography–mass spectrometry analysis produces characteristic iminium ions 2 Da lower than the parent compound, an artifact that can complicate forensic identification and requires lower injection temperatures to minimize.supported
Thermal degradation products identified for 18 cathinones including ethcathinone during GC-MS analysis. Iminium ions as degradation products. bkv099
comparative-pharmacology4 · 3 ok
The three-group classification proposed by Simmler et al. — DAT-preferential releasers, non-selective uptake inhibitors, and selective DAT/NET blockers — does not accommodate ethcathinone's hybrid mechanism (NET releaser, SERT releaser, DAT blocker without release).supported
Three pharmacological groups identified based on DAT/SERT selectivity. j.1476-5381.2012.02145.x
The three-group classification proposed by Simmler et al. — DAT-preferential releasers, non-selective uptake inhibitors, and selective DAT/NET blockers — does not accommodate ethcathinone's hybrid mechanism (NET releaser, SERT releaser, DAT blocker without release).supported
Ethcathinone (NEC) characterized as hybrid DAT blocker and 5-HT releaser. acsptsci.4c00299
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
The reduced DAT release potency is consistent with a lower abuse liability prediction for ethcathinone, as reinforcing properties of stimulants correlate with DAT-mediated dopamine efflux.supported
Three pharmacological groups identified based on DAT/SERT selectivity. j.1476-5381.2012.02145.x
receptor-pharmacology4 · 3 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Critically, functional release assays demonstrate that ethcathinone releases norepinephrine and serotonin from rat synaptosomes but does not release dopamine — it acts as a DAT blocker (reuptake inhibitor) rather than a DAT substrate (releaser).supported
Ethcathinone (NEC) characterized as hybrid DAT blocker and 5-HT releaser. acsptsci.4c00299
The classification of ethcathinone as a 5-HT releaser is based on functional synaptosome release assays reported in the 2024 SAR review rather than a specific binding constant.supported
Updated SAR review of 209+ synthetic cathinones. Ethcathinone (NEC) characterized as hybrid DAT blocker and 5-HT releaser. acsptsci.4c00299
The 2024 ACS SAR review classifies ethcathinone as a "hybrid compound" — a DAT blocker that also acts as a 5-HT releaser, an unusual combination within the cathinone family.supported
Ethcathinone (NEC) characterized as hybrid DAT blocker and 5-HT releaser. acsptsci.4c00299
pharmacokinetic-detail3 · 3 ok
Diethylpropion undergoes rapid and extensive first-pass hepatic metabolism, with only 3–4% of the parent drug remaining unchangedsupported
Diethylpropion is rapidly and extensively metabolized in humans...Only 3-4% unchanged drug excreted. pmid:2886596
Dangor et al. developed and validated a GLC method for simultaneous quantification of diethylpropion and ethcathinone in plasma, saliva, and urinesupported
GLC method for simultaneous determination. pmid:3790180
Sustained-release formulations of diethylpropion produce plateau ethcathinone plasma levels over 6–8 hours, reflecting the controlled release of the prodrug.supported
Sustained release provides plateau levels 6-8h post-dose. pmid:3663274
clinical-evidence1 · 1 ok
The sole published clinical case report of ethcathinone-associated toxicity was reported by Boulanger-Gobeil et al. in 2012, described by the authors as "to our knowledge the first case reported in the medical toxicology literature".supported
First reported case of ethcathinone and methylone poisoning in medical toxicology literature. s13181-011-0159-1